GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GSK PLC (LSE:GSK, NYSE:GSK) is approaching 18-month highs after the pharma group's boss Emma Walmsley raised the full-year outlook on the back of strong first-quarter results, with analysts saying performances are starting to allay long-held concerns. The shares rose 2.2% to £17.10 on Wednesday morning, within touching distance of the £17.25 highs earlier this year but still some way from pandemic highs towards £19 and all-time peaks above £20 in the dotcom era.

GSK beginning to alleviate long-held concerns, say analysts

GSK PLC (LSE:GSK, NYSE:GSK) has confirmed what recent prescription data hinted at: Its vaccines business is firing on all cylinders. Bumper sales of jabs for shingles and the cold-like condition RSV were the propellants behind better-than-expected numbers from the pharma giant.

GSK Q1 beats consensus and FY numbers upgraded after vaccines boost

GSK raised its full-year profit forecast on Wednesday, betting on strong demand for its common respiratory virus and shingles vaccines.

GSK raises full-year profit forecast

AstraZeneca

Novo Nordisk

Teva Pharmaceutical

The Federal Trade Commission is challenging hundreds of alleged “junk” patent listings filed by several pharmaceutical companies, which regulators claim could increase prices for medications like Novo Nordisk's diabetes drug Ozempic by making it harder to produce generic drugs.

FTC Warns ‘Junk Patents' Could Make Drugs Like Ozempic Pricier—Here's How

AbbVie

WASHINGTON — Federal regulators are challenging patents on 20 brand-name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.

FTC challenges ‘bogus' patents on Ozempic, other drugs that ‘block competition'

WisdomTree India Earnings Fund

GE Vernova LLC

Few experts expect the U.S. Federal Reserve to raise interest rates this year. And Fed Chairman Jerome Powell still has not ruled out the possibility of the central bank cutting rates in 2024.

Forget the Fed. These 3 Stocks Will Soar No Matter What

In the most recent trading session, GSK (GSK) closed at $40.91, indicating a +0.12% shift from the previous trading day.

Why the Market Dipped But GSK (GSK) Gained Today

BioNTech SE

Pfizer

GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines.

GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GSK (GSK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.

GSK Gears Up for Q1 Earnings: Here's What to Expect

The approval of GSK's 5-in-1 meningococcal ABCWY vaccine candidate, MenABCWY, could provide the broadest meningococcal serogroup coverage and lead to simplified immunization.

GSK Announces FDA Acceptance of New Meningococcal Jab BLA

GSK has delivered encouraging updates from ongoing trials of its vaccines for Shingles and Gonorrhoea. In the follow-up Zoster trial for the now on-sale Shingrix vaccine, efficacy was more than 80% for patients over 50 between 6-11 years after the jab with no new safety issues identified.

GSK encouraged by Shingles and Gonorrhoea trials

British drugmaker GSK said on Wednesday long-term data showed that its blockbuster shingles vaccine, Shingrix, had 79.7% efficacy in participants aged 50 years and above, six to 11 years after vaccination.

GSK says efficacy of its shingles vaccine remains high after years

GSK (GSK) closed at $40.80 in the latest trading session, marking a +0.27% move from the prior day.

GSK (GSK) Rises But Trails Market: What Investors Should Know

GSK (GSK) concluded the recent trading session at $41.19, signifying a +0.81% move from its prior day's close.

GSK (GSK) Rises Yet Lags Behind Market: Some Facts Worth Knowing

GSK is in good shape even with the overhang of the Zantac litigation according to analysts at Berenberg. Clear messaging on long-term targets and delivery in the interim is helping to build a more constructive dialogue with investors, says the broker.

GSK at a compelling valuation, suggests broker

GSK (GSK) concluded the recent trading session at $41.79, signifying a -1.49% move from its prior day's close.

GSK (GSK) Registers a Bigger Fall Than the Market: Important Facts to Note

Recently, Zacks.com users have been paying close attention to Glaxo (GSK). This makes it worthwhile to examine what the stock has in store.

GSK PLC Sponsored ADR (GSK) is Attracting Investor Attention: Here is What You Should Know

GSK (GSK) closed at $42.99 in the latest trading session, marking a +0.47% move from the prior day.

Here's Why GSK (GSK) Gained But Lagged the Market Today

Bio-Techne

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of GSK (GSK) and Techne (TECH). But which of these two stocks is more attractive to value investors?

GSK or TECH: Which Is the Better Value Stock Right Now?

GSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month in the United States. The company intends to start this in 2025.

GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US

Tokyo, Japan and Cambridge, UK, 21 March 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) announces it has regained full ownership from GSK of HTL0027477 (formerly GSK4381406), a clinic-ready, highly selective, first-in-class, oral GPR35 agonist in development as a potential new treatment for Inflammatory Bowel Diseases (IBD).

Sosei Heptares Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease

British pharmaceutical giant GSK said on Wednesday it will cap out-of-pocket costs at $35 per month for all its inhaled asthma and chronic lung disease medicines for eligible patients in the United States, following similar moves by two of its rivals.

GSK to cap out-of-pocket inhaler costs in US

Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates should drive the stock in the future quarters.

GSK Outperforms Industry on Strength in Key Drugs & Vaccines

In the most recent trading session, GSK (GSK) closed at $42.32, indicating a +0.43% shift from the previous trading day.

News for GlaxoSmithKline Stock (GSK)